{
  "success": false,
  "pagesUsed": [
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    17,
    18,
    19
  ],
  "modelUsed": "claude-opus-4-5",
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective - Body Weight Reduction",
        "text": "To demonstrate that tirzepatide 5 mg, 10 mg, and 15 mg once weekly is superior to placebo for body weight reduction at 72 weeks",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1",
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Objective - Body Weight at 20 Weeks Pooled Dose",
        "text": "To demonstrate that pooled tirzepatide 10 mg and 15 mg once weekly is superior to placebo for body weight reduction at 20 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Key Secondary Objective - Body Weight at 72 Weeks By Dose",
        "text": "To demonstrate that tirzepatide 10 mg and 15 mg once weekly separately is superior to placebo for body weight reduction including ≥20% body weight reduction from randomization at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Key Secondary Objective - SF-36v2 Physical Functioning at 72 Weeks Pooled Dose",
        "text": "To demonstrate that pooled tirzepatide 10 mg and 15 mg once weekly is superior to placebo for SF-36v2 acute form Physical Functioning domain score at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Key Secondary Objective - Lipid Parameters at 72 Weeks Pooled Dose",
        "text": "To demonstrate that tirzepatide (all doses combined) is superior to placebo for lipid parameters including non-HDL cholesterol and HDL cholesterol at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_6",
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Additional Secondary Objective - Lipid Parameters at 72 Weeks Pooled Dose",
        "text": "To evaluate the effect of tirzepatide (all doses combined) compared to placebo on lipid parameters including LDL cholesterol and total cholesterol at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_8",
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Safety Objective",
        "text": "To evaluate the safety and tolerability of tirzepatide once weekly compared to placebo in participants without type 2 diabetes who have obesity or are overweight with weight-related comorbidities",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_10",
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Objective - Progression to Type 2 Diabetes in Prediabetes Participants",
        "text": "To evaluate the effect of tirzepatide on progression to type 2 diabetes in participants with prediabetes at randomization during the additional 2-year treatment period",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Endpoint - Percent Change in Body Weight",
        "text": "Percent change from baseline in body weight at 72 weeks",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Primary Endpoint - Body Weight Reduction ≥5%",
        "text": "Proportion of participants achieving ≥5% body weight reduction from randomization at 72 weeks",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary Endpoint - Percent Change in Body Weight at 20 Weeks",
        "text": "Percent change from baseline in body weight at 20 weeks for pooled tirzepatide 10 mg and 15 mg doses",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "Key Secondary Endpoint - Body Weight Reduction ≥20% at 72 Weeks",
        "text": "Proportion of participants achieving ≥20% body weight reduction from randomization at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "name": "Key Secondary Endpoint - SF-36v2 Physical Functioning Domain Score",
        "text": "Change from baseline in SF-36v2 acute form Physical Functioning domain score at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "QualityOfLife",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "name": "Key Secondary Endpoint - Non-HDL Cholesterol",
        "text": "Change from baseline in non-HDL cholesterol at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "name": "Key Secondary Endpoint - HDL Cholesterol",
        "text": "Change from baseline in HDL cholesterol at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "name": "Additional Secondary Endpoint - LDL Cholesterol",
        "text": "Change from baseline in LDL cholesterol at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_9",
        "name": "Additional Secondary Endpoint - Total Cholesterol",
        "text": "Change from baseline in total cholesterol at 72 weeks",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_10",
        "name": "Safety Endpoint - Adverse Events",
        "text": "Incidence and severity of treatment-emergent adverse events",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_11",
        "name": "Safety Endpoint - Tolerability",
        "text": "Tolerability of tirzepatide as assessed by discontinuation rates due to adverse events",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Tolerability",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_12",
        "name": "Endpoint - Incident Diabetes",
        "text": "Incidence of type 2 diabetes in participants with prediabetes at randomization during the additional 2-year treatment period",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Estimand - Treatment Policy Strategy",
        "text": "Treatment effect on body weight reduction at 72 weeks in the ITT population using treatment policy strategy for intercurrent events",
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "strategy": {
              "code": "TreatmentPolicy",
              "codeSystem": "http://www.cdisc.org/USDM/strategy",
              "decode": "Treatment Policy"
            },
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand"
      }
    ]
  }
}